BGP-15 improves contractile function of regenerating soleus muscle

Area of Science:

• Muscle regeneration
• Biomedical research
• Pharmacology

Background:

• Muscle injuries can impair contractile function and lead to prolonged recovery.
• Heat shock proteins (HSPs) play a role in cellular protection and repair.
• O-[3-piperidino-2-hydroxy-1-propyl]-nicotinic amidoxime (BGP-15) is a known inducer of HSPs.

Purpose of the Study:

• To investigate the therapeutic potential of BGP-15 in enhancing the recovery of skeletal muscle.
• To evaluate the effects of BGP-15 on the morphology and contractile properties of regenerating soleus muscles.

Main Methods:

• Cryolesion model was used to induce injury in mouse soleus muscles.
• Mice were treated daily with BGP-15 (15 mg/Kg).
• Muscle morphology, contractile function, and protein expression (myosin heavy chains, HSP70, VDAC2) were assessed at day 10 post-injury.

Main Results:

• BGP-15 treatment did not reverse the decrease in myofiber cross-sectional area.
• BGP-15 significantly prevented the reduction in tetanic force and fatigue resistance.
• BGP-15 increased the expression of adult myosin heavy chain (MyHC-II, MyHC-I) and inducible 70-kDa heat shock protein (HSP70).

Conclusions:

• BGP-15 enhances functional recovery of regenerating soleus muscles, particularly in terms of strength and fatigue resistance.
• The beneficial effects are attributed to accelerated re-expression of adult MyHC isoforms and HSP70 induction.
• BGP-15 shows promise as a therapeutic agent for muscle injury recovery.